PH31556A - Method of inhibitin myeloperoxidase activity. - Google Patents

Method of inhibitin myeloperoxidase activity.

Info

Publication number
PH31556A
PH31556A PH49578A PH49578A PH31556A PH 31556 A PH31556 A PH 31556A PH 49578 A PH49578 A PH 49578A PH 49578 A PH49578 A PH 49578A PH 31556 A PH31556 A PH 31556A
Authority
PH
Philippines
Prior art keywords
inhibitin
myeloperoxidase activity
myeloperoxidase
activity
inhibitin myeloperoxidase
Prior art date
Application number
PH49578A
Other languages
English (en)
Inventor
Andrew L Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31556A publication Critical patent/PH31556A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH49578A 1993-12-21 1994-12-19 Method of inhibitin myeloperoxidase activity. PH31556A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,330 US5708009A (en) 1993-12-21 1993-12-21 Methods of inhibiting myeloperoxidase activity

Publications (1)

Publication Number Publication Date
PH31556A true PH31556A (en) 1998-11-03

Family

ID=22623358

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49578A PH31556A (en) 1993-12-21 1994-12-19 Method of inhibitin myeloperoxidase activity.

Country Status (16)

Country Link
US (2) US5708009A (de)
EP (1) EP0664125A1 (de)
JP (1) JPH07242546A (de)
KR (1) KR950016743A (de)
CN (1) CN1109884A (de)
AU (1) AU8154394A (de)
CA (1) CA2138513A1 (de)
CZ (1) CZ322794A3 (de)
HU (1) HUT72314A (de)
IL (1) IL112047A0 (de)
NO (1) NO944926L (de)
NZ (1) NZ270184A (de)
PH (1) PH31556A (de)
RU (1) RU94044489A (de)
TW (1) TW272939B (de)
ZA (1) ZA9410096B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
WO1996024356A1 (en) * 1995-02-06 1996-08-15 Eli Lilly And Company Methods of inhibiting effects of il-6
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
US6630453B1 (en) 1999-05-04 2003-10-07 Strakan Limited Androgen derivatives and uses thereof
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
CA2512021A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
DE602005020755D1 (de) * 2004-03-05 2010-06-02 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
US20090286813A1 (en) * 2006-04-13 2009-11-19 Astrazeneca Ab Thioxanthine Derivatives and Their Use as Inhibitors of MPO

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU672182B2 (en) * 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis

Also Published As

Publication number Publication date
JPH07242546A (ja) 1995-09-19
NZ270184A (en) 1999-07-29
CN1109884A (zh) 1995-10-11
US5708009A (en) 1998-01-13
NO944926L (no) 1995-06-22
EP0664125A1 (de) 1995-07-26
RU94044489A (ru) 1996-10-20
IL112047A0 (en) 1995-03-15
ZA9410096B (en) 1996-06-19
CA2138513A1 (en) 1995-06-22
CZ322794A3 (en) 1995-08-16
HU9403677D0 (en) 1995-02-28
AU8154394A (en) 1995-06-29
KR950016743A (ko) 1995-07-20
TW272939B (de) 1996-03-21
US5708010A (en) 1998-01-13
HUT72314A (en) 1996-04-29
NO944926D0 (no) 1994-12-19

Similar Documents

Publication Publication Date Title
EP0576178A3 (de) Verfahren zur Behaltung der Beziehung zwischen Elementen.
PH31556A (en) Method of inhibitin myeloperoxidase activity.
GR3025122T3 (en) A method of decontamination of food.
GB2232724B (en) Noise reduction method
ZA939369B (en) Method of milling.
PL310534A1 (en) Method of processing solid wastes
EP0667870A4 (de) Zusammensetzungen und verfahren zur modifizierung der regulatorischen aktivität von tgf-beta.
EP0608982A3 (de) Verfahren zur Inhibierung der Endotoxin-Aktivität.
GB2272566B (en) Decontamination method
EP0630383A4 (de) Methoden zur behandlung von diabetis.
ZA921107B (en) Method of treating Type I diabetes.
EP0555786A3 (en) Active noise cancellation system
EP0578138A3 (de) Verfahren zum Gennachweis.
GB2268433B (en) Method of punching parts
GB9205600D0 (en) Disinfecting method
EP0588556A3 (de) Verarbeitung von Maltodextrinen.
EP0637031A3 (de) Paralleler Prozessor und Herstellungsverfahren.
EP0657189A4 (de) Verfahren zum abbau einer halogenierten aromatischen verbindung.
GB9202196D0 (en) Method of treatment
GB2267547B (en) Chipper retainer assembly
PL297518A1 (en) Method of obtaining 4,6-dialkoxypyrimidines
EP0481082A4 (de) System zum definieren von symbolen einer speicherprogrammierbaren maschinensteuerung.
GB2289046B (en) An effluent treatment system
EP0449178A3 (en) Method for the reduction of star activity
EP0609766A3 (de) Verfahren zur Stabilisierung der Antigenität von Myeloperoxidase.